Bg pattern

ROLUFTA ELLIPTA 55 micrograms powder for inhalation (single dose)

Prescription review online

Prescription review online

A doctor will review your case and decide whether a prescription is medically appropriate.

Talk to a doctor about this medicine

Talk to a doctor about this medicine

Discuss your symptoms and possible next steps in a quick online consultation.

This page is for general information. Consult a doctor for personal advice. Call emergency services if symptoms are severe.
About the medicine

How to use ROLUFTA ELLIPTA 55 micrograms powder for inhalation (single dose)

Translated with AI

This page provides general information and does not replace a doctor’s consultation. Always consult a doctor before taking any medication. Seek urgent medical care if symptoms are severe.

Show original

Introduction

Package Leaflet: Information for the Patient

RoluftaEllipta55microgramsinhalation powder (single dose)umeclidinium (umeclidinium)

Read this entire leaflet carefully before starting to use this medicine, as it contains important information for you.

  • Keep this leaflet, as you may need to read it again.
  • If you have any further questions, ask your doctor, pharmacist, or nurse.
  • This medicine has been prescribed for you only. Do not pass it on to others. It may harm them, even if their symptoms are the same as yours.
  • If you experience any side effects, talk to your doctor, pharmacist, or nurse. This includes any possible side effects not listed in this leaflet. See section 4.

Contents of the package leaflet

  1. What is Rolufta Ellipta and what is it used for
  2. What you need to know before you start using Rolufta Ellipta
  3. How to use Rolufta Ellipta
  4. Possible side effects
  5. Storage of Rolufta Ellipta
  6. Contents of the pack and further information

Step-by-step instructions for use

1. What is Rolufta Ellipta and what is it used for

What is Rolufta Ellipta

Rolufta Ellipta contains the active substance umeclidinium (as bromide), which belongs to a group of medicines called bronchodilators.

What Rolufta Ellipta is used for

This medicine is used to treat chronic obstructive pulmonary disease (COPD)in adults. COPD is a long-term disease that gradually worsens, and the airways and air sacs in the lungs become blocked or damaged, making it difficult to breathe. This difficulty in breathing is added to the contraction of the muscles surrounding the airways, which makes these airways narrow and makes it difficult for air to flow.

This medicine prevents the contraction of these muscles in the lungs, making it easier for air to enter and leave the lungs. When used regularly, it helps control breathing difficulties and reduces the effects of COPD on daily life.

Rolufta Ellipta must not be used to relieve a sudden attack of shortness of breath or wheezing.

If you have this type of attack, you should use a fast-acting "rescue" inhaler (such as salbutamol). If you do not have a fast-acting inhaler, contact your doctor.

Doctor consultation

Not sure if this medicine is right for you?

Discuss your symptoms and treatment with a doctor online.

2. What you need to know before you start using Rolufta Ellipta

Do not use Rolufta Ellipta

  • if you are allergicto umeclidinium or any of the other ingredients of this medicine (listed in section 6).

If you think any of the above applies to you, do not usethis medicine until you have consulted your doctor.

Warnings and precautions

Talk to your doctor before starting to use Rolufta Ellipta:

  • if you have asthma(do not use Rolufta Ellipta to treat asthma)
  • if you have heart problems
  • if you have a type of eye problem called narrow-angle glaucoma
  • if you have enlarged prostate, difficulty urinating, or a blockage in the bladder
  • if you have severe liver problems.

Talk to your doctorif you think any of the above conditions apply to you.

Immediate breathing difficultiesIf you experience chest tightness, coughing, wheezing, or difficulty breathing immediately after using your Rolufta Ellipta inhaler:

stop using this medicineand seek medical attention immediately, as you may have a serious condition called paradoxical bronchospasm.

Eye problems during treatment with Rolufta Ellipta

If you experience eye pain or discomfort, blurred vision for a while, halos, or colored images associated with redness of the eyes during treatment with Rolufta Ellipta, stop using this medicine and seek medical help immediatelyas these signs may be due to an acute attack of narrow-angle glaucoma.

Children and adolescents

Do not give this medicine to children or adolescents under 18 years of age.

Other medicines and Rolufta Ellipta

Tell your doctor or pharmacist if you are taking, have recently taken, or might take any other medicines. If you are not sure what your medicine contains, talk to your doctor or pharmacist.

In particular, tell your doctor or pharmacist if you are taking other long-acting medicines to treat similar respiratory problems to this medicine, such as tiotropium. Do not use Rolufta Ellipta with these medicines.

Pregnancy and breastfeeding

If you are pregnant or breastfeeding, think you may be pregnant, or are planning to have a baby, ask your doctorfor advice before taking this medicine. If you are pregnant, do not use this medicine unless your doctor tells you to.

It is not known whether the components of Rolufta Ellipta can be excreted in breast milk. If you are breastfeeding, talk to your doctorbefore using Rolufta Ellipta.

If you are breastfeeding, do not use this medicine unless your doctor tells you to.

Driving and using machines

This medicine is unlikely to affect your ability to drive or use machines.

Rolufta Ellipta contains lactose

If your doctor has told you that you have an intolerance to some sugars, talk to them before using this medicine.

3. How to use Rolufta Ellipta

Follow the instructions for administration of this medicine exactly as told by your doctor. If you are unsure, talk to your doctor or pharmacist again.

The recommended doseis one inhalation every day, at the same time each day. You only need one inhalation a day, as the effect of this medicine lasts for 24 hours.

Do not use more doses than your doctor has told you to.

Use Rolufta Ellipta regularly

It is very important that you use Rolufta Ellipta every day, as your doctor has told you. This will help you not to have symptoms throughout the day and night.

Do notuse this medicine to relieve a sudden attack of shortness of breath or wheezing. If you have this type of attack, you should use a fast-acting "rescue" inhaler (such as salbutamol).

How to use the inhaler

To get the full instructions, read the "Step-by-step instructions for use" at the end of this leaflet.

The administration of Rolufta Ellipta is by inhalation. To use Rolufta Ellipta, breathe it into your lungs through your mouth using the Ellipta inhaler.

If your symptoms do not improve

If your COPD symptoms (shortness of breath, wheezing, coughing) do not improve or worsen, or if you are using your fast-acting "rescue" inhaler more often than usual:

contact your doctor as soon as possible.

If you use more Rolufta Ellipta than you should

If you accidentally use too much medicine, contact your doctor or pharmacist immediately, as you may need medical attention. If possible, show them the inhaler, packaging, or this leaflet. You may notice that your heart beats faster than normal, you have vision changes, or your mouth is dry.

If you forget to use Rolufta Ellipta

Do not inhale a double dose to make up for forgotten doses.Inhale the next dose at the usual time.

If you have wheezing or shortness of breath, use your fast-acting "rescue" inhaler (such as salbutamol) and seek medical advice.

If you stop using Rolufta Ellipta

Use this medicine for as long as your doctor recommends. It will only be effective for as long as you continue to use it. Do not stop using it until your doctor tells you to, even if you feel better, as your symptoms may worsen.

If you have any further questions on the use of this medicine, ask your doctor, pharmacist, or nurse.

Medicine questions

Started taking the medicine and have questions?

Discuss your symptoms and treatment with a doctor online.

4. Possible side effects

Like all medicines, this medicine can cause side effects, although not everybody gets them.

Allergic reactions

If after using Rolufta Ellipta you have any of the following symptoms, stop using this medicine and tell your doctor immediately:

Uncommon(may affect up to 1 in 100people):

  • itching
  • rash (hives) or redness.

Rare(may affect up to 1 in 1,000people):

  • wheezing (a whistling sound when breathing), coughing, or difficulty breathing
  • a sudden feeling of weakness or dizziness (which may cause collapse or loss of consciousness)

Other side effects:

Common(may affect up to 1 in 10people):

  • fast heart rate
  • pain when urinating and increased frequency (may be signs of a urinary tract infection)
  • common cold
  • nose and throat infection
  • cough
  • feeling of pressure or pain in the cheeks and forehead (may be symptoms of sinusitis, an inflammation of the sinuses)
  • headache
  • constipation
  • mouth and throat pain.

Uncommon(may affect up to 1 in 100people):

  • irregular heartbeat
  • sore throat
  • dry mouth
  • change in taste
  • hoarseness.

Rare(may affect up to 1 in 1,000people):

  • eye pain.

Frequency not known(frequency cannot be estimated from the available data):

  • decreased vision or eye pain due to increased eye pressure (possible signs of glaucoma)
  • blurred vision
  • increased eye pressure
  • difficulty and pain when urinating, which may be a sign of bladder obstruction or urinary retention
  • dizziness.

Reporting of side effects

If you experience any side effects, talk to your doctor, pharmacist, or nurse. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via the national reporting system listed in Appendix V.

By reporting side effects, you can help provide more information on the safety of this medicine.

5. Storage of Rolufta Ellipta

Keep this medicine out of the sight and reach of children.

Do not use this medicine after the expiry date which is stated on the packaging, tray, and inhaler, after EXP. The expiry date is the last day of the month stated.

Keep the inhaler in the sealed tray to protect it from moisture and only remove it immediately before the first use. Once the tray is opened, the inhaler can be used for a period of 6 weeks, counting from the date of opening of the tray. Write the date when the inhaler should be discarded in the space provided on the inhaler label. The date should be noted as soon as the inhaler is removed from the tray.

Do not store above 30°C.

If stored in a refrigerator, let the inhaler return to room temperature for at least one hour before use.

Medicines should not be disposed of via wastewater or household waste. Ask your pharmacist how to dispose of medicines no longer required. This will help protect the environment.

6. Container contents and additional information

Composition of Rolufta Ellipta

The active substance is umeclidinium (as bromide).

Each inhalation provides a delivered dose (dose that comes out of the mouthpiece) of 55 micrograms of umeclidinium (equivalent to 65 micrograms of umeclidinium bromide).

The other ingredients are lactose monohydrate (see section “Rolufta Ellipta contains lactose” in section 2) and magnesium stearate.

Appearance of the product and container contents

Rolufta Ellipta is a powder for inhalation (single-dose).

The Ellipta inhaler consists of a grey plastic body, a light green mouthpiece cover, and a dose counter. It is packaged in a laminated aluminium foil blister pack with a foldable aluminium foil lid. The blister pack contains a desiccant sachet to reduce moisture in the container.

The active substance is presented as a white powder in a blister pack inside the inhalator.

Rolufta Ellipta is available in packs of one inhaler containing 7 or 30 doses and in multipacks of 90 doses (3 inhalers of 30 doses). Not all pack sizes may be marketed.

Marketing authorisation holder:

GlaxoSmithKline Trading Services Limited

12 Riverwalk

Citywest Business Campus

Dublin 24

Ireland

Manufacturer:

Glaxo Wellcome Production

Zone Industrielle No.2

23 Rue Lavoisier

27000 Evreux

France

You can request more information about this medicinal product from the local representative of the marketing authorisation holder:

België/Belgique/Belgien

GlaxoSmithKline Pharmaceuticals s.a./n.v.

Tél/Tel: + 32 (0) 10 85 52 00

Lietuva

UAB “BERLIN-CHEMIE MENARINI BALTIC”

Tel: +370 52 691 947

[email protected]

Text in Bulgarian language with contact information of “Berlin-Chemie/A Menarini Bulgaria” including phone and email

Luxembourg/Luxemburg

GlaxoSmithKline Pharmaceuticals s.a./n.v.

Belgique/Belgien

Tél/Tel: + 32 (0) 10 85 52 00

Ceská republika

GlaxoSmithKline, s.r.o.

Tel: + 420 222 001 111

[email protected]

Magyarország

Berlin-Chemie/A. Menarini Kft.

Tel.:+36 23501301

[email protected]

Danmark

GlaxoSmithKline Pharma A/S

Tlf: + 45 36 35 91 00

[email protected]

Malta

GlaxoSmithKline Trading Services Limited

Tel: +356 80065004

Deutschland

BERLIN-CHEMIE AG

Tel: +49 (0) 30 67070

Nederland

GlaxoSmithKline BV

Tel: + 31 (0) 33 208110030

Eesti

OÜ Berlin-Chemie Menarini Eesti

Tel: +372 667 5001

[email protected]

Norge

GlaxoSmithKline AS

Tlf: + 47 22 70 20 00

Ελλ?δα

GlaxoSmithKline Μονοπρ?σωπη A.E.B.E.

Τηλ: + 30 210 68 82 100

Österreich

GlaxoSmithKline Pharma GmbH

Tel: + 43 (0)1 97075 0

[email protected]

España

FAES FARMA, S.A.

Tel.: +34 900 460 153

[email protected]

Polska

GSK Services Sp. z o.o.

Tel.: + 48 (0)22 576 9000

France

Laboratoire GlaxoSmithKline

Tél: + 33 (0)1 39 17 84 44

[email protected]

Portugal

GlaxoSmithKline – Produtos Farmacêuticos, Lda.

Tel: + 351 21 412 95 00

[email protected]

Hrvatska

Berlin-Chemie Menarini Hrvatska d.o.o.

Tel: +385 1 4821 361

[email protected]

România

GlaxoSmithKline Trading Services Limited

Tel: +40 800672524

Ireland

GlaxoSmithKline (Ireland) Limited

Tel: + 353 (0)1 4955000

Slovenija

Berlin-Chemie / A. Menarini Distribution Ljubljana d.o.o.

Tel: +386 (0)1 300 2160

[email protected]

Ísland

Vistor hf.

Sími: + 354 535 7000

Slovenská republika

Berlin-Chemie / A. Menarini Distribution Slovakia s.r.o.

Tel: +421 2 544 30 730

[email protected]

Italia

  • Menarini Industrie Farmaceutiche Riunite s.r.l.

Tel: +39-055 56801

Suomi/Finland

GlaxoSmithKline Oy

Puh/Tel: + 358 (0)10 30 30 30

Κ?προς

GlaxoSmithKline Trading Services Limited

Τηλ: +357 80070017

Sverige

GlaxoSmithKline AB

Tel: + 46 (0)8 638 93 00

[email protected]

Latvija

SIA Berlin-Chemie/Menarini Baltic

Tel: +371 67103210

[email protected]

United Kingdom (Northern Ireland)

GlaxoSmithKline Trading Services Limited

Tel: + 44 (0)800 221441

[email protected]

Date of last revision of this leaflet:

Other sources of information

Detailed information on this medicinal product is available on the European Medicines Agency website: http://www.ema.europa.eu.

Step-by-step instructions for use

What is the Ellipta inhaler?

The first time you use Rolufta Ellipta, you do not need to check that the inhaler is working correctly, as it contains pre-measured doses and is ready to use directly.

Your Rolufta Ellipta inhaler contains:

Open box with leaflet, inhaler, tray with desiccant and tray lid shown individually

The inhaler is packaged in a tray. Do not open the tray until you are ready to start using your new inhaler. When you are ready to use the inhaler, remove the lid to open the tray. The tray contains a desiccantsachet, to reduce moisture. Discard the desiccant sachet, do notopen, ingest or inhale it.

Hand disposing of empty blister pack in waste bin with “Waste” label and blister pack with tablets still present

When you remove the inhaler from its tray, it will be in the “closed” position. Do not open the inhaler until you are ready to inhale a dose of medicine. When the tray is opened, write the “Discard by” date on the space provided on the inhaler label. The “Discard by” date is 6 weeks from the date of opening the tray. After this date, the inhaler should not be used. The tray can be discarded once it is opened.

If stored in a refrigerator, allow the inhaler to reach room temperature for at least one hour before use.

The step-by-step instructions for the Ellipta inhaler provided below can be used for both the 30-dose inhaler (30 days of treatment) and the 7-dose inhaler (7 days of treatment).

  1. Read this information before starting

If the inhaler cover is opened and closed without inhaling the medicine, the dose will be lost. The lost dose will be retained safely inside the inhaler, but it will not be available for inhalation.

It is not possible to accidentally administer an extra dose or a double dose through a single inhalation.

Inhaler with dose counter showing number 30 and arrow indicating opening of top cover with curved lines

  1. Prepare a dose

Wait until you are ready to inhale a dose before opening the inhaler cover.

Do not shake the inhaler.

  • Slide the cover down until you hear a ‘click’.

Inhaler device with mouthpiece and ventilation slots showing direction of rotation with arrow and “Click” sound

Now the medicine is ready to inhale.

As confirmation, the dose counter decreases by 1unit.

  • If the dose counter does not decrease when you hear the ‘click’, the inhaler will not release the dose of medicine.

Take it to your pharmacist and ask for help.

  1. Inhale your medicine
  • Hold the inhaler away from your mouth and breathe out as much as you can.

Do notbreathe out into the inhaler.

  • Place the mouthpiece between your lips, and close your lips firmly around the mouthpiece.

Do notblock the ventilation slots with your fingers.

Profile of face with inhaler mouthpiece in mouth and hands holding it, arrow indicates position of lips

  • Take a long, steady, deep breath in. Hold your breath for as long as possible (at least 3-4 seconds).
  • Take the inhaler out of your mouth.
  • Breathe out slowly and gently.

You may not be able to taste or feel the medicine, even when you use the inhaler correctly.

Beforeclosing the cover, the inhaler mouthpiece can be cleaned using a dry cloth.

  1. Close the inhaler

Medical device with retractable cover showing direction of rotation and number 29 on the bottom

  • Slide the cover up, until it clicks, to cover the mouthpiece.

Online doctors for ROLUFTA ELLIPTA 55 micrograms powder for inhalation (single dose)

Discuss questions about ROLUFTA ELLIPTA 55 micrograms powder for inhalation (single dose), including use, safety considerations and prescription review, subject to medical assessment and local regulations.

5.0 (69)
Doctor

Tarek Agami

General medicine 11 years exp.

Dr. Tarek Agami is a general practitioner registered in both Portugal and Israel, with broad experience in family and preventive medicine. He offers online consultations for adults and children, providing personalised support for primary care needs, chronic disease management, and everyday health concerns.

Dr. Agami received clinical training and worked in leading medical institutions in Israel (Kaplan Medical Center, Barzilai Medical Center, Wolfson Medical Center) and Portugal (European Healthcare City, Viscura Internacional, Hospital Dr. José Maria Grande, Hospital Vila Franca de Xira). His approach combines international medical standards with individualised attention to each patient.

Main areas of consultation:

  • Diagnosis and treatment of acute and chronic conditions (high blood pressure, diabetes, respiratory infections, cardiovascular symptoms)
  • Evaluation of symptoms and guidance on further diagnostic testing
  • Preventive check-ups and regular health monitoring
  • Medical support during travel or after relocation
  • Treatment adjustments and lifestyle recommendations based on your personal history
Dr. Agami provides medical support for patients using GLP-1 medications (such as Ozempic or Mounjaro) as part of a weight loss strategy. He offers individualised treatment planning, regular follow-up, dose adjustment, and advice on combining medication with sustainable lifestyle changes. Consultations follow the medical standards accepted in Portugal and Israel.

Dr. Agami is committed to evidence-based, patient-centred care, ensuring that each person receives trusted medical support tailored to their health goals.

Camera Book a video appointment
€69
5.0 (63)
Doctor

Nuno Tavares Lopes

Family medicine 18 years exp.

Dr. Nuno Tavares Lopes is a licensed physician in Portugal with 17 years of experience in emergency medicine, family and general practice, and public health. He is the Director of Medical and Public Health Services at an international healthcare network and serves as an external consultant for the WHO and ECDC.

  • Emergency care: infections, fever, chest/abdominal pain, minor injuries, paediatric emergencies
  • Family medicine: hypertension, diabetes, cholesterol, chronic disease management
  • Travel medicine: pre-travel advice, vaccinations, fit-to-fly certificates, travel-related illnesses
  • Sexual and reproductive health: PrEP, STD prevention, counselling, treatment
  • Weight management and wellness: personalised weight loss programmes, lifestyle guidance
  • Skin and ENT issues: acne, eczema, allergies, rashes, sore throat, sinusitis
  • Pain management: acute and chronic pain, post-surgical care
  • Public health: prevention, health screenings, long-term monitoring
  • Sick leave (Baixa médica) connected to Segurança Social in Portugal
  • IMT medical certificates for driving licence exchange
Dr. Nuno Tavares Lopes provides medical support for patients using GLP-1 medications (Mounjaro, Wegovy, Ozempic, Rybelsus) as part of a weight loss strategy. He offers individualised treatment planning, regular follow-up, dose adjustment, and advice on combining medication with sustainable lifestyle changes. Consultations follow the medical standards accepted in Europe.

Dr. Lopes also provides interpretation of medical tests, follow-up care for complex patients, and multilingual support. Whether for urgent concerns or long-term care, he helps patients act with clarity and confidence.

Camera Book a video appointment
€59
5.0 (17)
Doctor

Anastasiia Shalko

Family medicine 13 years exp.

Dr. Anastasiia Shalko is a general practitioner with a background in both paediatrics and general medicine. She graduated from Bogomolets National Medical University in Kyiv and completed her paediatric internship at the P.L. Shupyk National Medical Academy of Postgraduate Education. After working as a paediatrician in Kyiv, she relocated to Spain, where she has been practising general medicine since 2015, providing care for both adults and children.

Her work focuses on urgent, short-term medical concerns – situations where patients need quick guidance, symptom assessment and clear next steps. She helps people understand whether their symptoms require in-person evaluation, home management or a change in treatment. Common reasons for booking an online consultation include:

  • acute respiratory symptoms (cough, sore throat, runny nose, fever)
  • viral illnesses such as colds and seasonal infections
  • gastrointestinal complaints (nausea, diarrhoea, abdominal pain, gastroenteritis)
  • sudden changes in how a child or adult feels
  • questions about existing treatment and whether adjustments are needed
  • renewal of prescriptions when clinically appropriate
Dr. Shalko works specifically with urgent and short-term problems, providing practical recommendations and helping patients determine the safest next step. She explains symptoms clearly, guides patients through decision-making and offers straightforward medical advice for everyday acute issues.

She does not provide long-term management of chronic conditions, ongoing follow-up or comprehensive care plans for complex long-term illnesses. Her consultations are designed for acute symptoms, sudden concerns and situations where timely medical input is important.

With clinical experience in both paediatrics and general medicine, Dr. Shalko confidently supports adults and children. Her communication style is clear, simple and reassuring, helping patients feel informed and supported throughout the consultation.

Camera Book a video appointment
€50
5.0 (3)
Doctor

Tomasz Grzelewski

Dermatology 21 years exp.

Dr Tomasz Grzelewski is an MD, PhD specialist in allergy, paediatrics, general practice and sports medicine, with a clinical focus on dermatology, endocrinology, allergology and sports-related health. He has more than 20 years of clinical experience and completed his medical training at the Medical University of Łódź, where he defended his PhD thesis with distinction. His doctoral research was recognised by the Polish Society of Allergology for its innovative contribution to the field. Throughout his career, he has gained extensive expertise in diagnosing and managing a wide range of allergic and paediatric conditions, including modern allergen desensitisation techniques.

For five years, Dr Grzelewski served as the Head of two paediatric departments in Poland, managing complex clinical cases and leading multidisciplinary teams. He also worked in medical centres in the United Kingdom, gaining experience across both primary care and specialist environments. With over a decade of telemedicine experience, he has provided online consultations across Europe and is valued for his clear, structured and evidence-based medical guidance.

Dr Grzelewski is actively involved in clinical programmes focused on modern anti-allergic therapies. As a Principal Investigator, he leads research projects on sublingual and oral allergen desensitisation, supporting evidence-based progress in allergy treatment for both children and adults.

In addition to his background in allergology and paediatrics, he completed dermatology studies through the Cambridge Education Group (Royal College of Physicians of Ireland) and a Clinical Endocrinology course at Harvard Medical School. This advanced training enhances his ability to manage skin manifestations of allergies, atopic conditions, urticaria, endocrine-related symptoms and complex immunological reactions.

Patients commonly seek his care for:

  • seasonal and perennial allergies
  • allergic rhinitis and chronic nasal symptoms
  • asthma and breathing difficulties
  • food and medication allergies
  • urticaria, atopic dermatitis and skin reactions
  • recurrent infections in children
  • sports-related health questions
  • general family medicine concerns
Dr Tomasz Grzelewski is known for his clear communication style, structured medical approach and ability to explain treatment options in a concise and accessible way. His multidisciplinary background across allergy, paediatrics, dermatology and endocrinology allows him to provide safe, up-to-date and comprehensive care for patients of all ages.
Camera Book a video appointment
€80
0.0 (0)
Doctor

Daniel Cichi

Family medicine 24 years exp.

Dr Daniel Cichi is a family medicine doctor with over 20 years of clinical experience. He provides online consultations for adults, supporting patients with acute symptoms, chronic conditions, and everyday health concerns that require timely medical guidance.

His background includes work in emergency care, ambulance services, and family medicine, which allows him to assess symptoms quickly, identify warning signs, and help patients choose the safest next steps – whether that means home care, treatment adjustment, or in-person evaluation.

Patients commonly consult Dr Daniel Cichi for:

  • acute symptoms: fever, infections, flu-like illness, cough, sore throat, shortness of breath;
  • chest discomfort, palpitations, dizziness, fatigue, and blood pressure concerns;
  • digestive problems: abdominal pain, nausea, diarrhoea, constipation, reflux;
  • muscle, joint, and back pain, minor injuries, post-traumatic symptoms;
  • chronic conditions: hypertension, diabetes, high cholesterol, thyroid disorders;
  • review and interpretation of lab tests, imaging reports, and medical documents;
  • medication review and treatment adjustment;
  • medical advice while travelling or living abroad;
  • second opinions and guidance on whether in-person care is needed.
Dr Cichi’s consultations are structured and practical. He focuses on clear explanations, risk assessment, and actionable recommendations, helping patients understand their symptoms and make informed decisions about their health.
Camera Book a video appointment
€55

Frequently Asked Questions

Is a prescription required for ROLUFTA ELLIPTA 55 micrograms powder for inhalation (single dose)?
ROLUFTA ELLIPTA 55 micrograms powder for inhalation (single dose) requires a prescription in Spain. You can check with a doctor online whether this medicine may be appropriate for your situation.
What is the active substance in ROLUFTA ELLIPTA 55 micrograms powder for inhalation (single dose)?
The active ingredient in ROLUFTA ELLIPTA 55 micrograms powder for inhalation (single dose) is umeclidinium bromide. This information helps identify medicines with the same composition but different brand names.
How much does ROLUFTA ELLIPTA 55 micrograms powder for inhalation (single dose) cost in pharmacies?
The average pharmacy price for ROLUFTA ELLIPTA 55 micrograms powder for inhalation (single dose) is around 45.27 EUR. Prices may vary depending on the manufacturer and dosage form.
Who manufactures ROLUFTA ELLIPTA 55 micrograms powder for inhalation (single dose)?
ROLUFTA ELLIPTA 55 micrograms powder for inhalation (single dose) is manufactured by Glaxosmithkline Trading Services Limited. Pharmacy brands and packaging may differ depending on the distributor.
Which doctors can assess the use of ROLUFTA ELLIPTA 55 micrograms powder for inhalation (single dose) online?
Doctors such as Family doctors, Psychiatrists, Dermatologists, Cardiologists, Endocrinologists, Gastroenterologists, Pulmonologists, Nephrologists, Rheumatologists, Hematologists, Infectious disease physicians, Allergists, Geriatricians, Paediatricians, Oncologists may assess whether ROLUFTA ELLIPTA 55 micrograms powder for inhalation (single dose) is appropriate, depending on your situation and local regulations. You can book an online consultation to discuss your symptoms and possible next steps.
What are the alternatives to ROLUFTA ELLIPTA 55 micrograms powder for inhalation (single dose)?
Other medicines with the same active substance (umeclidinium bromide) include INCRUSE ELLIPTA 55 mcg INHALATION POWDER, SINGLE-DOSE, ATROALDO 20 micrograms/PUFF pressurized inhalation solution, ATROVENT 20 micrograms PRESSURIZED INHALATION SOLUTION. These may have different brand names or formulations but contain the same therapeutic ingredient. Always consult a doctor before switching or starting a new medicine.
bg-pattern-dark

Stay informed about Oladoctor

News about new services, product updates and useful information for patients.

Follow us on social media